Efficacy and safety of left atrial appendage occlusion in atrial fibrillation patients with chronic kidney disease: a systematic review and meta-analysis

doi:10.31083/j.rcm.2020.03.62

Reviews in Cardiovascular Medicine

2020, Vol. 21

Issue (3): 443-451 DOI: 10.31083/j.rcm.2020.03.62

Systematic Review

Previous articles | Next articles

Efficacy and safety of left atrial appendage occlusion in atrial fibrillation patients with chronic kidney disease: a systematic review and meta-analysis

Hai-Fu Zhang^1,², Qin-Xia Zhang², Yuan-Yuan Zhang¹, Dong Yang¹, Zhao Xu¹, Qi-Bin Jiao^1,², Xing-Wei Zhang^1,^2,^*(

)

¹Division of Cardiology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou 310015, P. R. China
²School of Medicine, Hangzhou Normal University, Hangzhou 311121, P. R. China

Download: PDF(348KB) ( 697 ) Full text ( 43 )
Export: BibTeX | EndNote (RIS)

Abstract:

Atrial fibrillation (AF) is the most common arrhythmia among the elderly, and more frequently occur in those with chronic kidney disease (CKD). Left atrial appendage occlusion (LAAO) is used as a mechanical alternative approach for prevention of AF-related thromboembolisms. This meta-analysis was conducted to provide suggestions for the clinical application of LAAO in AF patients with CKD. The incidence of perioperative adverse events and other clinical effects after operation was by a single rate meta-analysis. Results showed that incidence of adverse events in the perioperative period after LAAO was generally low, with only pericardial effusion / tamponade (1.90%) and mortality rate (1.10%). During the follow-up period, the incidence of stroke/transient ischemic attack (TIA) and bleeding were 2.17% and 4.53%, respectively. A low incidence rate of adverse events was found in the perioperative period following LAAO. These results indicate that LAAO more effectively prevents the occurrence of stroke/TIA and minimizes bleeding events than oral anticoagulants.

Key words: Atrial fibrillation chronic kidney disease left atrial appendage occlusion

Submitted: 15 April 2020 Revised: 24 July 2020 Accepted: 27 July 2020 Published: 30 September 2020

Fund:
LQ18H020006/Natural Science Foundation of Zhejiang Province of China
0020190126/Health and Technology Plan of Hangzhou City
2017ZD02/Health and Technology Plan of Hangzhou City

^*Corresponding Author(s): Xing-Wei Zhang E-mail: xwzhang@hznu.edu.cn

	Service
	E-mail this article
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Hai-Fu Zhang
	Qin-Xia Zhang
	Yuan-Yuan Zhang
	Dong Yang
	Zhao Xu
	Qi-Bin Jiao
	Xing-Wei Zhang

Cite this article:

Hai-Fu Zhang, Qin-Xia Zhang, Yuan-Yuan Zhang, Dong Yang, Zhao Xu, Qi-Bin Jiao, Xing-Wei Zhang. Efficacy and safety of left atrial appendage occlusion in atrial fibrillation patients with chronic kidney disease: a systematic review and meta-analysis. Reviews in Cardiovascular Medicine, 2020, 21(3): 443-451.

URL:

https://rcm.imrpress.com/EN/10.31083/j.rcm.2020.03.62 OR https://rcm.imrpress.com/EN/Y2020/V21/I3/443

Fig. 1. Preferred reporting items for systematic reviews and meta-analyses flow diagram. Using different keywords, a total of 1829 articles were retrieved. Through reading title, abstract and full-text, there were 7 relevant articles finally included in our meta-analysis. CKD: chronic kidney disease.

Fig. 2. Quality evaluation char. Select bias and performance bias were higher because of the inclusion of non-randomized controlled trial.

Table 1. Characteristics of 7 studies included in the review

Study	Study design	Age	Male (%)	CHADS-VASc/CHADS	HAS-BLED	Treatment group (n)	Renal function	Previous Stroke/TIA (%)	Previous Major Bleeding (%)
Luani et al. (2019)	cohort study	75.9 $\pm$ 6.7	57.5	4.5 $\pm$ 1.4	3.6 $\pm$ 1.0	Watchman: 73	eGFR $<$ 60 mL/min	16.4	/
Kefer et al. (2016)	RCT	77.9 $\pm$ 7.3	54.7	4.9 $\pm$ 1.5	3.4 $\pm$ 1.3	ACP: 375	eGFR $<$ 60 mL/min	32.3	49.1
Brockmeyer et al. (2019)	cohort study	78.2 $\pm$ 7.3	49.4	4.7 $\pm$ 1.3	3.9 $\pm$ 0.9	ACP: 61 Watchman: 5 Amplatzer Amulet: 14	eGFR $<$ 60 mL/min	17.3	39.6
Genovesi et al. (2018)	prospective cohort study	71.8 $\pm$ 9.6	76	4.0 $\pm$ 1.5	4.4 $\pm$ 0.9	Watchman: 24 Amplatzer Amulet: 26	eGFR $<$ 15 mL/min, on dialysis	20	66
Xue et al. (2018)	RCT	77.0 $\pm$ 7.2	60.9	4.3 $\pm$ 1.5	4.0 $\pm$ 1.0	Watchman: 151	eGFR $<$ 60 mL/min	11.3	25.8
So et al. (2018)	retrospective study	72 $\pm$ 8	65.3	5.1 $\pm$ 1.5	3.4 $\pm$ 0.1	ACP/Amulet: 71	eGFR $<$ 60 mL/min	/	/
Della Rocca et al. (2018)	cohort study	77 $\pm$ 7	46.1	4.9 $\pm$ 1.8	3.7 $\pm$ 0.9	104	eGFR $<$ 60 mL/min	/	/
NOTE: RCT: randomized controlled trial; eGFR: estimated glomerular filtration rate; TIA: transient ischemic attack.

Fig. 3. Forest plots showing the effect of clinical outcomes on the overall risk of perioperative death, stroke/ transient ischemic attack, bleeding, pericardial effusion/tamponade. A total of 7 studies were included. During the perioperative period, mortality rate was 1.10% (OR:0.01, 95%CI: 0.00-0.05). The incidence of stroke/TIA and bleeding in the perioperative period was 1.40% (OR:0.02, 95%CI: 0.01-0.03) and 1.60% (OR:0.02,95%CI: 0.00-0.13). The pericardial effusion/tamponade rate was 1.90% (OR:0.02, 95%CI: 0.00-0.10).

Fig. 4. A forest plot showing the effect of left atrial appendage occlusion on the overall risk of stroke/ transient ischemic attack, bleeding, all-cause death and cardiogenic death in the follow up time. A total of 6 studies were included. The incidence of stroke/TIA and bleeding in the follow up time was 2.17% (OR:0.03, 95%CI: 0.02-0.05) and 4.53% (OR:0.04, 95%CI: 0.02-0.07). All-cause mortality was 12.28% (OR:0.12, 95%CI: 0.09-0.17), and the cardiogenic mortality rate was 3.98% (OR:0.04, 95%CI: 0.03-0.07) during follow-up.

Fig. 5. Forest plots of the meta-analysis comparing the clinical outcomes after left atrial appendage occlusion in patients with or without chronic kidney disease. Patients with CKD exhibited higher all-cause mortality rate after undergoing LAAO (RR:2.00; 95%CI: 1.09-3.68, P

<

0.05). There were no significant differences in stroke/TIA (RR: 0.52, P = 0.24), bleeding (RR: 1.02,

P

= 0.96) and cardiac death (RR: 1.34, P = 0.65).

[1]	Akagi, Y., Chiba, T., Uekusa, S., Kato, H., Yamamura, S., Aoki, Y., Enoki, M., Ogawara, Y., Kasahara, T., Kimura, Y., Shimizu, T., Takeishi, A., Nakajima, Y., Kobayashi, H. and Sugi, K. (2019) Retrospective cohort study of the efficacy and safety of dabigatran: real-life dabigatran use including very low-dose 75 mg twice daily administration. Journal of Pharmaceutical Health Care and Sciences 5, 17.
[2]	Bajwa, R. J., Kovell, L., Resar, J. R., Arbab-Zadeh, A., Mandal, K., Calkins, H. and Berger, R. D. (2017) Left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation. Clinical Cardiology 40, 825-831.
[3]	Black-Maier, E., Piccini, J. P. and Granger, C. B. (2019) Left atrial appendage closure: A therapy uniquely suited for specific populations of patients with atrial fibrillation. Journal of Cardiovascular Electrophysiology 30, 2968-2976.
[4]	Boersma, L. V. A., Schmidt, B., Betts, T. R., Sievert, H., Tamburino, C., Teiger, E., Pokushalov, E., Kische, S., Schmitz, T., Stein, K. M. and Bergmann, M. W. (2016) Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. European Heart Journal 37, 2465-2474.
[5]	Boersma, L. V., Ince, H., Kische, S., Pokushalov, E., Schmitz, T., Schmidt, B., Gori, T., Meincke, F., Protopopov, A. V., Betts, T., Foley, D., Sievert, H., Mazzone, P., De Potter, T., Vireca, E., Stein, K. and Bergmann, M. W. (2017) Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial. Heart Rhythm 14, 1302-1308.
[6]	Boersma, L. V., Ince, H., Kische, S., Pokushalov, E., Schmitz, T., Schmidt, B., Gori, T., Meincke, F., Protopopov, A. V., Betts, T., Mazzone, P., Foley, D., Grygier, M., Sievert, H., De Potter, T., Vireca, E., Stein, K., Bergmann, M. W. and following investigators and institutions participated in the EWOLUTION study (2019) Evaluating Real-World Clinical Outcomes in Atrial Fibrillation Patients Receiving the WATCHMAN Left Atrial Appendage Closure Technology. Circulation: Arrhythmia and Electrophysiology 12, e006841.
[7]	Bohula, E. A., Giugliano, R. P., Ruff, C. T., Kuder, J. F., Murphy, S. A., Antman, E. M. and Braunwald, E. (2016) Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 trial. Circulation 134, 24-36.
[8]	Brockmeyer, M., Wolff, G., Krieger, T., Lin, Y., Karathanos, A., Afzal, S., Zeus, T., Westenfeld, R., Polzin, A., Heinen, Y., Perings, S., Kelm, M., Medical Faculty, CARID – Cardiovascular Research Institute Düsseldorf, Heinrich-Heine-University, Düsseldorf, Germany and Schulze, V. (2019) Kidney function stratified outcomes of percutaneous left atrial appendage occlusion in patients with atrial fibrillation and high bleeding risk. Acta Cardiologica 18, 1-9.
[9]	Chalikias, G., Drosos, I. and Tziakas, D. N. (2016) Prevention of contrast-induced acute kidney injury: an update. Cardiovascular Drugs and Therapy 30, 515-524.
[10]	Coleman, C. I., Evidence-Based Practice Center, Hartford Hospital, Hartford, CT, USA, Kreutz, R., Sood, N., Bunz, T. J., Meinecke, A., Eriksson, D., Baker, W. L. and Evidence-Based Practice Center, Hartford Hospital, Hartford, CT, USA (2019) Rivaroxaban’s impact on renal decline in patients with nonvalvular atrial fibrillation: a US marketscan claims database analysis. Clinical and Applied ThrombosisHemostasis 25, 107602961986853.
[11]	Dalia, A. A., Kuo, A., Vanneman, M., Crowley, J., Elhassan, A. and Lai, Y. (2020) Anesthesiologists Guide to the 2019 AHAACCHRS focused update for the management of patients with atrial fibrillation. Journal of Cardiothoracic and Vascular Anesthesia 34, 1925-1932.
[12]	Della Rocca, D. G., Gasperetti, A., Fassini, G., Mohanty, S., Trivedi, C., Natale, V. N., Horton, R., Gianni, C., Al-Ahmad, A. and Burkhardt, J. D. J. C. (2018) Safety and clinical effectiveness of left atrial appendage occlusion in patients with chronic kidney disease.Circulation 138, A12696-A12696.
[13]	Diener, H., Connolly, S. J., Ezekowitz, M. D., Wallentin, L., Reilly, P. A., Yang, S., Xavier, D., Di Pasquale, G. and Yusuf, S. (2010) Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. The Lancet Neurology 9, 1157-1163.
[14]	Fox, K. A. A., Piccini, J. P., Wojdyla, D., Becker, R. C., Halperin, J. L., Nessel, C. C., Paolini, J. F., Hankey, G. J., Mahaffey, K. W., Patel, M. R., Singer, D. E. and Califf, R. M. (2011) Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. European Heart Journal 32, 2387-2394.
[15]	Genovesi, S., Slaviero, G., Porcu, L., Casu, G., Bertoli, S., Sagone, A., Pieruzzi, F., Rovaris, G., Buskermolen, M., Danna, P., Montoli, A., Oreglia, J., Contaldo, G. and Mazzone, P. (2018) Implant success and safety of left atrial appendage occlusion in end stage renal disease patients: Peri-procedural outcomes from an Italian dialysis population. International Journal of Cardiology 262, 38-42.
[16]	Godino, C., Melillo, F., Bellini, B., Mazzucca, M., Pivato, C. A., Rubino, F., Figini, F., Mazzone, P., Della Bella, P., Margonato, A., Colombo, A. and Montorfano, M. (2020) Percutaneous left atrial appendage closure versus non-vitamin K oral anticoagulants in patients with non-valvular atrial fibrillation and high bleeding risk. Eurointervention 15, 1548-1554.
[17]	Hohnloser, S. H., Hijazi, Z., Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden, Thomas, L., Alexander, J. H., Amerena, J., Hanna, M., Keltai, M., Lanas, F., Lopes, R. D., Lopez-Sendon, J., Granger, C. B. and Wallentin, L. (2012) Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. European Heart Journal 33, 2821-2830.
[18]	Holmes, D. R., Reddy, V. Y., Turi, Z. G., Doshi, S. K., Sievert, H., Buchbinder, M., Mullin, C. M. and Sick, P. (2009) Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. The Lancet 374, 534-542.
[19]	January, C. T., Wann, L. S., Calkins, H., Chen, L. Y., Cigarroa, J. E., Cleveland, J. C., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., Furie, K. L., Heidenreich, P. A., Murray, K. T., Shea, J. B., Tracy, C. M. and Yancy, C. W. (2019) 2019 AHAACCHRS focused update of the 2014 AHAACCHRS guideline for the management of patients with atrial fibrillation: A Report of the American College of CardiologyAmerican Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons. Circulation 140, e125-e151.
[20]	Kefer, J., Tzikas, A., Freixa, X., Shakir, S., Gafoor, S., Nielsen-Kudsk, J. E., Berti, S., Santoro, G., Aminian, A., Landmesser, U., Nietlispach, F., Ibrahim, R., Danna, P. L., Benit, E., Budts, W., Stammen, F., De Potter, T., Tichelbäcker, T., Gloekler, S., Kanagaratnam, P., Costa, M., Cruz-Gonzalez, I., Sievert, H., Schillinger, W., Park, J., Meier, B. and Omran, H. (2016) Impact of chronic kidney disease on left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation. International Journal of Cardiology 207, 335-340.
[21]	Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H. C., Heidbuchel, H., Hendriks, J., Hindricks, G., Manolis, A. S., Oldgren, J., Popescu, B. A., Schotten, U., Van Putte, B., Vardas, P. and ESC Scientific Document Group (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal 37, 1359-1469.
[22]	Kreidieh, B., Rojas, F., Schurmann, P., Dave, A. S., Kashani, A., Rodríguez-Mañero, M. and Valderrábano, M. (2015) Left atrial appendage remodeling after lariat left atrial appendage ligation. Circulation: Arrhythmia and Electrophysiology 8, 1351-1358.
[23]	La-Viola, B. and Guerra, C. G. (2018) Risky business: judging the use of non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in patients with renal dysfunction. Journal of Atrial Fibrillation 11, 2017.
[24]	Levey, A. S., de Jong, P. E., Coresh, J., Nahas, M. E. L., Astor, B. C., Matsushita, K., Gansevoort, R. T., Kasiske, B. L. and Eckardt, K. (2011) The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney International 80, 17-28.
[25]	Luani, B., Genz, C., Herold, J., Mitrasch, A., Mitusch, J., Wiemer, M., Schmeißer, A., Braun-Dullaeus, R. C. and Rauwolf, T. (2019) Cerebrovascular events, bleeding complications and device related thrombi in atrial fibrillation patients with chronic kidney disease and left atrial appendage closure with the WATCHMAN™ device. BMC Cardiovascular Disorders 19, 112.
[26]	Malyszko, J., Lopatowska, P., Mlodawska, E., Musialowska, D., Malyszko, J. S. and Tomaszuk-Kazberuk, A. (2018) Atrial fibrillation in kidney transplant recipients: is there a place for the novel drugs?. Nephrology Dialysis Transplantation 33, 1304-1309.
[27]	Mtwesi, V. and Amit, G. (2019) Stroke prevention in atrial fibrillation. Medical Clinics of North America 103, 847-862.
[28]	Noble, R. and Taal, M. W. (2019) Epidemiology and causes of chronic kidney disease. Medicine 47, 562-566.
[29]	Nombela-Franco, L., Rodés-Cabau, J., Cruz-Gonzalez, I., Freixa, X., Asmarats, L., Gutiérrez, H., Sahay, S., Rodriguez-Gabella, T., Moreno-Samos, J. C., Tirado-Conte, G., Goncalves-Ramirez, L. R., Rama-Merchan, J. C., Amat-Santos, I. J., O’Hara, G., Martín-Yuste, V., Bethencourt, A., Jimenez-Quevedo, P. and Macaya, C. (2018) Incidence, predictors, and prognostic value of acute kidney injury among patients undergoing left atrial appendage closure. JACC: Cardiovascular Interventions 11, 1074-1083.
[30]	Osmancik, P., Tousek, P., Herman, D., Neuzil, P., Hala, P., Stasek, J., Haman, L., Kala, P., Poloczek, M., Branny, M., Chovancik, J., Cervinka, P., Holy, J., Vancura, V., Rokyta, R., Taborsky, M., Kovarnik, T., Zemanek, D., Peichl, P., Haskova, S., Jarkovsky, J. and Widimsky, P. (2017) Interventional left atrial appendage closure vs novel anticoagulation agents in patients with atrial fibrillation indicated for long-term anticoagulation (PRAGUE-17 study). American Heart Journal 183, 108-114.
[31]	Potpara, T. S., Ferro, C. J. and Lip, G. Y. H. (2018) Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction. Nature Reviews Nephrology 14, 337-351.
[32]	Reddy, V. Y., Doshi, S. K., Kar, S., Gibson, D. N., Price, M. J., Huber, K., Horton, R. P., Buchbinder, M., Neuzil, P., Gordon, N. T. and Holmes, D. R. (2017) 5-year outcomes after left atrial appendage closure. Journal of the American College of Cardiology 70, 2964-2975.
[33]	Reddy, V. Y., Möbius-Winkler, S., Miller, M. A., Neuzil, P., Schuler, G., Wiebe, J., Sick, P. and Sievert, H. (2013) Left atrial appendage closure with the watchman device in patients with a contraindication for oral anticoagulation. Journal of the American College of Cardiology 61, 2551-2556.
[34]	Shamseer, L., Moher, D., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P., Stewart, L. A. and the PRISMA-P Group (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 349, g7647-g7647.
[35]	Shin, J., Secora, A., Alexander, G. C., Inker, L. A., Coresh, J., Chang, A. R. and Grams, M. E. (2018) Risks and benefits of direct oral anticoagulants across the spectrum of GFR among incident and prevalent patients with atrial fibrillation. Clinical Journal of the American Society of Nephrology 13, 1144-1152.
[36]	Siontis, K. C., Dr Siontis’ current affiliation is the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN., Zhang, X., Eckard, A., Bhave, N., Schaubel, D. E., He, K., Tilea, A., Stack, A. G., Balkrishnan, R., Yao, X., Department of Health Sciences Research, Division of Health Care Policy and Research (X.Y., N.D.S.), Mayo Clinic, Rochester, MN., Noseworthy, P. A., Department of Cardiovascular Medicine (P.A.N.), Mayo Clinic, Rochester, MN., Shah, N. D., Department of Health Sciences Research, Division of Health Care Policy and Research (X.Y., N.D.S.), Mayo Clinic, Rochester, MN., Saran, R., Kidney Epidemiology and Cost Center, School of Public Health (A.E., K.H., R.S.), University of Michigan, Ann Arbor., Nallamothu, B. K. and Institute for Healthcare Policy and Innovation (B.K.N.), University of Michigan, Ann Arbor. (2018) Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States. Circulation 138, 1519-1529.
[37]	So, C. Y., Cheung, G. S. H., Chan, C. K. Y., Kam, K. K. H., Chan, A. K. Y., Au, S. S. W., Chan, S. K. C., Lam, Y. Y., Lee, A. P. W. and Yan, B. P. Y. (2018) Effect of chronic kidney disease on left atrial appendage occlusion outcome: a single-centre retrospective analysis. Journal of the American College of Cardiology 71, A302.
[38]	Tomson, C. and Duffy, S. (2019) Management of chronic kidney disease. Medicine 47, 567-575.
[39]	Vuddanda, V. L. K., Turagam, M. K., Umale, N. A., Shah, Z., Lakkireddy, D. R., Bartus, K., McCausland, F. R., Velagapudi, P., Mansour, M. and Heist, E. K. (2020) Incidence and causes of in-hospital outcomes and 30-day readmissions after percutaneous left atrial appendage closure: A US nationwide retrospective cohort study using claims data. Heart Rhythm 17, 374-382.
[40]	Xue, X., Jiang, L., Duenninger, E., Muenzel, M., Guan, S., Fazakas, A., Cheng, F., Illnitzky, J., Keil, T. and Yu, J. (2018) Impact of chronic kidney disease on Watchman implantation: experience with 300 consecutive left atrial appendage closures at a single center. Heart and Vessels 33, 1068-1075.
[41]	Zhang, L., Steckman, D. A., Adelstein, E. C., Schulman-Marcus, J., Loka, A., Mathew, R. O., Venditti, F. J. and Sidhu, M. S. (2019) Oral anticoagulation for atrial fibrillation thromboembolism prophylaxis in the chronic kidney disease population: the State of the Art in 2019. Cardiovascular Drugs and Therapy 33, 481-488.

[1]	Yin-jun Mao, Hang Wang, Jian-xing Chen, Pin-fang Huang. Meta-analysis of medical management versus catheter ablation for atrial fibrillation[J]. Reviews in Cardiovascular Medicine, 2020, 21(3): 419-432.
[2]	Meer Fakhry, Mandeep S. Sidhu, Sripal Bangalore, Roy O. Mathew. Accelerated and intensified calcific atherosclerosis and microvascular dysfunction in patients with chronic kidney disease[J]. Reviews in Cardiovascular Medicine, 2020, 21(2): 157-162.
[3]	Anthony (Ming-yu) Chuang, Mau T Nguyen, Woon-Man Kung, Sam Lehman, Derek P Chew. High-sensitivity troponin in chronic kidney disease: Considerations in myocardial infarction and beyond[J]. Reviews in Cardiovascular Medicine, 2020, 21(2): 191-203.
[4]	Omar Kousa, Mohamed Mansour, Dana Awad, Amr Essa, Abdallah Qasim, Arindam Sharma, Mark Holmberg. Reversible bradycardia secondary to myxedema coma: case-report[J]. Reviews in Cardiovascular Medicine, 2020, 21(2): 297-301.
[5]	Guicheng Liang, Beizhu Xu, Shirong Wang, Chengxuan Li, Guoqiang Zhong. Imaging with intracardiac echocardiography compared to transesophageal echocardiography during left atrial appendage occlusion[J]. Reviews in Cardiovascular Medicine, 2020, 21(1): 93-101.
[6]	Michele Provenzano, Giuseppe Coppolino, Teresa Faga, Carlo Garofalo, Raffaele Serra, Michele Andreucci. Epidemiology of cardiovascular risk in chronic kidney disease patients: the real silent killer[J]. Reviews in Cardiovascular Medicine, 2019, 20(4): 209-220.
[7]	M. Usmaan Bashir, Anjali Bhagra, Suraj Kapa, Christopher J. McLeod. Modulation of the autonomic nervous system through mind and body practices as a treatment for atrial fibrillation[J]. Reviews in Cardiovascular Medicine, 2019, 20(3): 129-137.
[8]	Davide Bolignano, Anna Pisano, Graziella D’Arrigo. Pulmonary hypertension: a neglected risk condition in renal patients?[J]. Reviews in Cardiovascular Medicine, 2018, 19(4): 117-121.
[9]	Sivakumar Sudhakaran, Teodoro Bottiglieri, Kristen M. Tecson, Aaron Y. Kluger, Peter A. McCullough. Alteration of lipid metabolism in chronic kidney disease, the role of novel antihyperlipidemic agents, and future directions[J]. Reviews in Cardiovascular Medicine, 2018, 19(3): 77-88.
[10]	Peter A. McCullough, Aaron Y. Kluger, Kristen M. Tecson, Clay M. Barbin, Andy Y. Lee, Edgar V. Lerma, Zachary P. Rosol, Sivan L. Kluger, Janani Rangaswami. Inhibition of the Sodium–Proton Antiporter (Exchanger) is a Plausible Mechanism of Potential Benefit and Harm for Drugs Designed to Block Sodium Glucose Co-transporter 2[J]. Reviews in Cardiovascular Medicine, 2018, 19(2): 51-63.
[11]	Claudio Ronco, Federico Ronco, Peter A. McCullough. A Call to Action to Develop Integrated Curricula in Cardiorenal Medicine[J]. Reviews in Cardiovascular Medicine, 2017, 18(3): 93-99.
[12]	Molly Orosey, Lohit Garg, Sahil Agrawal, Manyoo Agarwal, Jinu J. John, David E. Haines >, Wai Shun Wong. Atrioesophageal Fistula Following Radiofrequency Catheter Ablation of Atrial Fibrillation[J]. Reviews in Cardiovascular Medicine, 2017, 18(3): 115-122.
[13]	Sandeep K. Krishnan, Norman E. Lepor. Acute and Chronic Cardiovascular Effects of Hyperkalemia: New Insights Into Prevention and Clinical Management[J]. Reviews in Cardiovascular Medicine, 2016, 17(S1): 9-21.
[14]	Rohit Kumar, Aref M. Rahman, Brian L. Henry. A Review of the Clinical Subgroup Analyses From the RE-LY Trial[J]. Reviews in Cardiovascular Medicine, 2016, 17(1-2): 40-48.
[15]	Peter A. McCullough, Maria Rosa Costanzo, Marc Silver, Bruce Spinowitz, Jun Zhang, Norman E. Lepor. Novel Agents for the Prevention and Management of Hyperkalemia[J]. Reviews in Cardiovascular Medicine, 2015, 16(2): 140-155.

No Suggested Reading articles found!

Viewed

Full text

Abstract

Cited

Shared

Discussed

Home

About

Articles

Special issues

For authors

For reviewers

Alerts

Contact us

Cite this article:

URL: